Congress , May 2018 London, UK

Transcription

1 Feature Speakers Congress 23, May London, UK Successfully Driving Business Partnerships And Showcasing Innovation In The Microbiome Field Isabelle De Cremoux David Berry John Hambour Andrew Morgan Dr David Cook Cheryl Zimberlin General Partner CEO Benefits of Attending: Learn which start ups are developing the most 1 innovative microbiome therapeutic, diagnostic, and nutritional solutions and why you should invest in them now Showcase your novel microbiome research or 2 product on our Pitch your Microbes Innovation Stage to gain investment and form collaborations with investors, and pharmaceutical and nutrition leaders of external innovation Understand the challenges that leading microbiome 3 biotechnology companies have experienced and overcome to allow you to develop a successful commercialisation plan Director of Research Beyond Borders DuPont Fellow & Chief Scientist Determine how to navigate the regulatory pathway 4 for microbiome therapeutics and diagnostics to form successful development plan for your microbiome product and achieve market launch Forge new collaborations and business partnerships 5 with leading nutrition and pharmaceutical companies and investors to secure funding and research partners through our meeting mojo platform Chief Scientific Officer Healthcare Associate 1

2 Meeting Who you MOJO WILL MEET: Emerging Early Stage Microbiome Companies Academics Looking to Commercialise Venture Capital and Private Equity Investors Intellectual Property Lawyers Market Intelligence and Consultancy Providers Heathcare Investment Banks Established Microbiome Biotechnology Companies Regulatory Experts Strategic partnership and External Innovation Leads from Pharmaceutical and Nutrition Companies Microbiome Invest : YOUR MICROBIOME NETWORKING WISHLIST With close to 400 microbiome start-ups in 2017 compared to just 12 in 2013, the microbiome industry has experienced an exponential growth, with an increasing number of Biotech and Pharmaceutical companies seeking to capitalise on the translation of research into clinically and commercially viable medicine. Over $616.9 million has been invested in microbiome companies in 2016, more than all venture investment in the microbiome space in 2011 to 2015 combined. In addition to the open networking available throughout the Forum s networking breaks and receptions, our MEETING MOJO platform allows you to create a bespoke meeting schedule, ensuring you connect with the industry stakeholders that are most important in building your business. Login details for the MEETING MOJO platform will be sent to all registered attendees 4 weeks prior to the event to allow for connections to be made online and scheduling to occur. Productive networking guaranteed! Following the success of the inaugural 2017 Microbiome Invest event, we are incredibly excited to present this exclusive one-day event, held in London on 23rd May. Connecting over 100 industry executives from early-stage microbiome start-ups, nutrition and pharmaceutical companies, venture capital and private equity investors, regulatory experts and ground-breaking solution providers. 2

3 Speaker SPOTLIGHT Adrian Ferrero CO-founder and CEO Andrew Morgan DuPont Fellow & Chief Scientist Marie Drago Founder Artem Khlebinkov Director of Strategic Partnerships Isabelle De Cremoux CEO David Berry General Partner Cheryl Zimberlin Healthcare Associate Derek Butler CEO Jim Weston Vice President and Head of Regulatory Affairs Dr David Cook Chief Scientific Officer John Hambour Director of Research Beyond Borders Luc Sterkman CEO Mike Romanos Chief Executive Officer Oron Assaf Chief Business Officer 3

4 Pitch your MICR BES Selection Committee Central to the Microbiome Invest is Pitch Your Microbes, a platform for 12 of the most exciting emerging companies in the microbiome space to pitch their innovative ideas to a room full of potential investors, collaborators and partners. Our esteemed selection committee will handpick these final 12 presenting companies from the list of all applicants. TO APPLY, YOU SHOULD MEET ONE OF THE FOLLOWING ENTRY CRITERIA: Isabelle De Cremoux CEO David Berry General Partner A recent spin-out from an academic institution looking for investment, partnerships and advice An academic with a desire to develop and commercialise an innovative idea or piece of research biotech company at the pre-revenue or post-revenue stage, looking for investment, A partnerships and advice Dr David Cook Chief Scientific Officer You do not need to be a registered company you just need an innovative idea that could form the basis of a new product or service in the translational microbiome field! TO APPLY, COMPLETE THE ONLINE APPLICATION FORM. DEADLINE: APRIL 2ND. Sponsorship OPPORTUNITES Far from the typical meet-and-greet exhibition experience, you as a sponsor or exhibitor will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list. With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. CONTACT US: Ask us about the different ways you can get involved. Contact our sponsorship team to find out more about each package by ing partner@kisacoresearch.com or by calling: +44 (0)

5 Pitch your MICR BES MICROBIOME INVEST Pitch your Microbes Winner 2017 Follow in the footsteps of our previous presenting companies at Pitch Your Microbes Microbiome Invest At Microbiome Invest 2017, Gallinée won the Pitch Your Microbes competition, securing a year s access to the Johnson & Johnson Innovation, JLINX Facility. Marie Drogo Founder The Microbiome Invest Congress was such an amazing event for Gallinée. Not only did I meet great people like S-Biomedic and AnimalBiome, we also got in contact with very interesting investors. Learn about the successes and challenges our Pitch your Microbes 2017 finalists have experienced since the event during the Where Are They Now? panel on this year s agenda. We just closed a deal with Unilever Ventures thanks to people we met at your event. My advice to start-ups is to focus on building your product early, test it, lead your vision with associated data and a pilot study, then create this around your real customers needs and feedback. Don t focus all your efforts on investment too early, it is more important to demonstrate what your product will achieve. Marie Drogo, Founder, Gallinée Shannon Doyle, Founder, Smart Flora 5

6 AGENDA 23, May 8.30 Registration 8.50 Chairman s Opening Remarks David Cook, EVP of R&D and Chief Scientific Officer, Seres Therapeutics 9.00 KEYNOTE: Global Microbiome Future Innovation, Partnerships, And Trends Exciting recent investments and developments in the microbiome space Upcoming microbiome trigger points with technologies and disease focuses to watch in and beyond Isabelle de Cremoux, CEO, Seventure Partners 9.20 How-To Prepare For The Progression And Challenges For Microbiome Products Of Different Modalities Single strain bacteria-how much evidence of durable clinical efficacy do you need? Have you got a defendable IP? Consortia of bacteria-how robust are your manufacturing processes and are costs manageable? Microbiome-derived small molecules-what is the pathway for these? John Hambor, Director, Research Beyond Borders, Boehringer Ingelheim 9.40 Pitch Your Microbes 3 pre-selected emerging companies pitch their innovative ideas Azitra Inc. Ilya Pharma OptiBiotix Ltd Morning Networking Break And Meeting Mojo Private Prescheduled Meeting Interval Private Prescheduled Meeting Interval Private Prescheduled Meeting PANEL: The Journey Of A Microbiome Biotech Important considerations when launching your company How to ensure your IP is robust The commercialisation process - working with regulators and industry advisors Challenges you will face along the way and lessons that can be learnt from other microbiome start-ups at different stages Panellists: David Cook, EVP of R&D and Chief Scientific Officer, Seres Therapeutics Mike Romanos, CEO, Microbiotica Luc Sterkman, CEO, Caelus Health B.V 6

7 AGENDA PANEL: In Conversation With: Investors and pharmaceutical and nutrition companies discuss investment in the microbiome-what are investors and industry looking for in start-ups and academic collaborations in the microbiome space? What evidence do investors/industry need from start ups for serious collaboration/investment talks to begin? How much data and IP should start-ups have to begin talks with investors and industry? Lessons learnt from previous investments-what start-ups should avoid to ensure success What is the future of microbiome diagnostics and therapeutics in healthcare? Moderator: Cheryl Zimberlin, Healthcare Associate, Merck Ventures Panellists: David Berry, General Partner, Flagship Ventures Isabelle de Cremoux, CEO, Seventure Partners Andrew Morgan, DuPont Fellow and Chief Scientist, DuPont Nutrition & Health John Hambor, Director, Research Beyond Borders, Boehringer Ingelheim Artem Khlebinkov, Director of Strategic Partnerships, Danone Nutrica Research Pitch Your Microbes 3 pre-selected emerging companies pitch their innovative ideas Perfood GmbH Carbiotix AB Lavivo Networking Lunch And Meeting Mojo Private Prescheduled Meeting Interval Private Prescheduled Meeting Interval Private Prescheduled Meeting Pitch Your Microbes 3 pre-selected emerging companies pitch their innovative ideas ConsortiaTX ImmuneBiotech AB TargEDys SA PANEL: Where Are They Now? Find out where the companies that presented at Microbiome Invest 2017 are now, lessons they have learnt during their experiences and plans for and beyond Panellists: Marie Drago, CEO, Gallinée Derek Butler, CEO and Co-founder, MyMicroZoo Assaf Oron, CBO, MBcure Adrian Ferrero Fernandez, Co-founder & CEO, Biome Makers Inc. 7

8 AGENDA Regulation And Market Launch Of Microbiome Products It is known that the FDA prioritise safety over efficacy-the panel will discuss whether this is a commonly held view across regulatory bodies in Europe and how emerging companies should plan their research with this in mind How should start-ups plan trials, collect data and develop their microbiome products to ensure they pass regulatory hurdles and can successfully launch onto the market? MHRA, EMA and FDA-how are they looking at microbiome products and how can you make sure your product is successful? How will the regulatory bodies require you to standardise protocols and manufacturing processes to allow your microbiome product to enter the market Pitch Your Microbes 3 pre-selected emerging companies pitch their innovative ideas BioMe Oxford Biomica Ltd. Civet Biosciences Microbiome Innovation in Animal Health Oliver Hardcastle, CEO, Anizome LLC The potential for microbiome-based solutions in farm and companion animals Close of Conference Jim Weston, Head of Regulatory Affairs, Seres Therapeutics A representative from the MHRA Afternoon Networking Break And Meeting Mojo Private Prescheduled Meeting Interval Private Prescheduled Meeting Interval Private Prescheduled Meeting This was an excellent focussed event for the microbiome community whether biotech, pharma or investor to exchange views, speculate on the future and network. Mike Romanos, Microbiotica 8

9 Series CALENDAR FEBRUARY 5 th -7 th San Diego, USA 8-9 CANCER MICROBI ME CONGRESS th Boston, USA 21th -22nd NE W The Microbiome as a New Frontier in the Etiology & Treatment of Cancer! 3 0 th -31 s t Boston, USA Website TBC NOVEMBER 2 7 th -2 9 th The Microbiome as a new Frontier; from Cosmetics to Dermatology. NE W Translating Academic Research into Clinically & Commercially Viable Therapeutics Manipulating the Animal Microbiome! London, UK Promoting Partnerships and Showcasing The Latest Innovation in The Microbiome Field JUNE 2 0 th -21 s t NE W Kansas City, USA MAY 2 3 rd MAY MARCH MAY th Translating Academic Research into Clinically & Commercially Viable Therapeutics Manipulating the Animal Microbiome Paris, France animalmicrobiomecongress.com One of the most important things is to bring together people who have different expertise and all sorts of skills. There is no single person, no single institution which has all the knowledge that we need. Networking is absolutely crucial. Professor Dusko Ehrlich, Head of Research and Founder, GM, INRA 9

10 Venue and PRICING Microbiome Invest is taking place in London, United Kingdom. Venue details to be confirmed. Pricing Information EARLY BIRD PASS TYPE Book by 16th March Academics, Biotech Companies (Under 3 Years Old), & Investors STANDARD PRICING 499 +VAT 599 Pharmaceutical, Nutrition & Biotech Companies (Over 3 Years Old) 1,399 +VAT 1,599 Service Providers (Including Investment Bankers, Lawyers, Consultants) 1,599 +VAT 1,899 BOOK A TEAM TO SAVE MORE! Industry Rates Only: Team discounts cannot be combined with any other discount or offer Book a Team of 3+ Save an Additional 10% Off Book a Team of 5+ Save an Additional 15% Off INTERESTED IN SPONSORSHIP? Please contact Mark Gavhure, Manager Commercial Partnerships +44(0) partner@kisacoresearch.com Payment Terms: Please note that a 49 GBP processing fee will apply to any invoices requested. All Prices are in GBP and are exclusive of 20% All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer Please view our Cancellation Policy QUESTIONS? Please events@kisacoresearch.com 10